Combination therapy with gemcitabine, CSF1R blockade and either anti‐CTLA4 or anti‐PD1 therapy resulted in a synergistic response that was further enhanced with co‐blockade of both PD‐1 and CTLA‐4 with complete tumor regression in 30% of animals and an average tumor regression of 85%.52 Here, CSF1R is linked to neoplasm.